Lucrative opportunities for new entrants to invigorate 'stagnant' bipolar market, says GlobalData

18 March 2016

A considerable dearth of products to meet patient needs means there are significant opportunities within a declining bipolar market, reports research and consulting firm GlobalData.

The report describes the current bipolar pipeline as ‘sparse’. Only two treatments – Otsuka (TYO: 4578) and Lundbeck (LUND: CO) drug Abilify Maintena (aripiprazole) and ITI-007, licensed from Bristol-Myers Squibb (NYSE: BMY) – are expected to receive regulatory approval by 2024.

GlobalData forecasts that Abilify Maintena will achieve sales of $643 million in 2024 across the eight major markets of the US, France, Germany, Italy, Spain, UK, Japan and Canada.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK